Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
Fedoseienko A, Wieringa HW, Wisman GB, Duiker E, Reyners AK, Hofker MH, van der Zee AG, van de Sluis B, van Vugt MA. Fedoseienko A, et al. Among authors: van vugt ma, van de sluis b, van der zee ag. PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016. PLoS One. 2016. PMID: 27788210 Free PMC article.
The role of ATM and 53BP1 as predictive markers in cervical cancer.
Roossink F, Wieringa HW, Noordhuis MG, ten Hoor KA, Kok M, Slagter-Menkema L, Hollema H, de Bock GH, Pras E, de Vries EG, de Jong S, van der Zee AG, Schuuring E, Wisman GB, van Vugt MA. Roossink F, et al. Among authors: van vugt ma, van der zee ag. Int J Cancer. 2012 Nov 1;131(9):2056-66. doi: 10.1002/ijc.27488. Epub 2012 Mar 29. Int J Cancer. 2012. PMID: 22323184 Free PMC article.
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.
Reyners AKL, de Munck L, Erdkamp FLG, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga ANM, Polee M, Hollema H, van Vugt MATM, Schaapveld M, Willemse PHB; DoCaCel Study Group. Reyners AKL, et al. Ann Oncol. 2012 Nov;23(11):2896-2902. doi: 10.1093/annonc/mds107. Epub 2012 Jun 11. Ann Oncol. 2012. PMID: 22689176 Free article. Clinical Trial.
Breaking the DNA damage response to improve cervical cancer treatment.
Wieringa HW, van der Zee AG, de Vries EG, van Vugt MA. Wieringa HW, et al. Among authors: van vugt ma, van der zee ag. Cancer Treat Rev. 2016 Jan;42:30-40. doi: 10.1016/j.ctrv.2015.11.008. Epub 2015 Nov 24. Cancer Treat Rev. 2016. PMID: 26643553 Review.
107 results